Immuneering (IMRX) Change in Accured Expenses (2020 - 2026)

Immuneering's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$247323.0 for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 39.62% year-over-year to -$247323.0 in Q1 2026; TTM through Mar 2026 was -$12341.0, a 137.51% decrease from a year earlier, with the FY2025 full-year figure at $57848.0, up 321.6% from the prior year.
• Change in Accured Expenses fell to -$247323.0 in Q1 2026 per IMRX's latest filing, from $211424.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $2.1 million in Q2 2023 and bottomed at -$2.2 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $66608.0 (2024), against an average of $29350.7.
• Across the five-year window, Change in Accured Expenses soared 2432.12% in 2022 and plunged 521.93% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $430006.0 in 2022, then soared by 240.5% to $1.5 million in 2023, then tumbled by 88.12% to $174008.0 in 2024, then grew by 21.5% to $211424.0 in 2025, then plunged by 216.98% to -$247323.0 in 2026.
• Per Business Quant, the three latest IMRX Change in Accured Expenses figures stand at -$247323.0 (Q1 2026), $211424.0 (Q4 2025), and $304594.0 (Q3 2025).